A Phase 2 interventional study of Nitric Oxide gas at 160ppm in Non-Tuberculous Mycobacterial Pneumonia, sponsored by University of British Columbia. Completed at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2020-07-29.
Sponsored by University of British Columbia · Phase 2, Interventional, and Treatment
An open labeled Study (NCT03331445) is demonstrating encouraging safety and efficacy results for most subjects receiving 160ppm nitric oxide gas (gNO) for treatment of non-tuberculous mycobacteria (NTM) over a 15 day treatment regimen. In one subject, who had a reduction in sputum culture concentration of Bacterium bolletii from plus 3 to plus 1 corresponding to a 2-3 log10 cfu/gm reduction during the treatment, the one-week post treatment follow-up sputum culture had increased to plus 2. It is hypothesized that a longer treatment period may be necessary to fully eradicate NTM from the sputum culture in chronic lung disease. This study will extend the period of gNO exposure for a prolonged period of time (3 months) to attempt to fully eradicate the NTM in this single subject. This study will transition from the medical clinic to supervised delivery in the patient's home environment.
Primary Objective: Determine the efficacy of prolonged delivery of inhaled nitric oxide to treat an adult patient with pulmonary NTM Primary Endpoint: Eradication of NTM growth in sputum cultures. Efficacy will be assessed by the antimicrobial effect of inhaled NO on the density of NTM species and other microorganisms in the sputum.
Secondary Objective(s): Determine the safety \& efficacy of inhaled nitric oxide
Secondary Endpoint(s):
Safety
Efficacy
Exclusion Criteria:
For women of child bearing potential:
Nitric Oxide 160ppm for 50-80 minutes two -three times a day for 365 days
Drug: Nitric Oxide gas at 160ppm
Nitric oxide gas at 160 ppm inhaled three times daily for 50-80 min delivered with air as the carrier via inhalation for a maximum total of 90 days (extended 365 days twice). Total dose of 480 ppm hours per day.
Also known as: Thiolanox
Eradication of NTM in sputum
The primary efficacy variable for this study is eradication of recovered NTM organisms in sputum colony forming unit (CFU) g (log 10) from baseline. Eradication will be defined as two negative sputum cultures post nitric oxide gas treatment over 60 days.
Time frame: 365 days
Mean absolute change in forced expiratory volume at one second (FEV1)% from baseline.
Clinical Measurement of Mean absolute change in FEV1% from baseline to Day 365 (within group test).
Time frame: 365 days
Mean change in distance walked in the six-minute walk test from baseline
Clinical Measurement of Mean change in distance walked in the six-minute walk test from baseline.
Time frame: 365 days
Mean change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) scores for each domain from baseline
Clinical Measurement of Mean change in CFQ-R scores for each domain from baseline. Each domain measure the magnitude of severity for each of the 8 items. Respondents score each item using a 5-point likert scale ranging from 0 (no symptom) to 4 (the highest magnitude of severity). For item 1 (difficult to breathe), item 2 (feel feverish), item 3 (tired), item 6 (mucus), and item 7 (chest tightness) the response options are: 0=No symptom, 1=a little, 2=somewhat, 3=a good deal, 4=a great deal. For item 4 (chills/sweats), item 5 (cough), and item 8 (wheezing) the response options are: 0=no symptom, 1=slightly, 2=moderately, 3=very, 4=extremely.
Time frame: 365 days
Recurrence of NTM in sputum culture post NTM eradication.
Measurement of recovered NTM organisms in sputum colony forming unit (CFU) g (log 10) post eradication. Eradication will be defined as two negative sputum cultures post nitric oxide gas treatment over 60 days.
Time frame: 30 and 60 days post NTM eradication
Nitric oxide delivery effect on clinical values in home delivery
Safety measured as evaluated by the number of unanticipated adverse events in clinical labs (hematology, coagulation, and serum chemistries).
Time frame: 365 days
Nitric oxide delivery effect on key physiologic vital signs in home delivery
Safety measured as evaluated by the number of unanticipated adverse events in vitals signs (blood pressure, respiratory rate) and oxygen saturation levels during NO delivery.
Time frame: 365 days
Nitric oxide effect on delivery parameter concentrations in home delivery
Safety measured as evaluated by the number of unanticipated adverse events with inspired concentration of nitric oxide (NO), oxygen (O2) and nitrogen dioxide (NO2) delivered to subject.
Time frame: 365 days
Nitric oxide delivery effect on systemic methemoglobin levels in home delivery
Safety measured as evaluated by the number of unanticipated adverse events in pulseoixmetric arterial methemoglobin percent levels during nitric oxide delivery.
Time frame: 365 days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia